Current best evidence on prescribed drugs

Pills
Drugdocs Logo

Current best evidence on prescribed drugs

Pills
HomeDrugsDRUGDOCS AIAboutNewsGlossaryContact
HomeDrugsAIAboutNewsGlossaryContact

DRUG ▾

ABCDEFGHIJKLMNOPQRSTUVWXYZ

DRUG

CLASS

AI

News

Capmatinib

(Tabrecta®)

Tabrecta®

Drug updated on 12/11/2024

Dosage FormTablet (oral; 150 mg, 200 mg)
Drug ClassKinase inhibitors
Ongoing and
Completed Studies		ClinicalTrials.gov

Indication

  • Indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • This summary is based on the review of four systematic review(s)/meta-analysis(es). [1-4]
  • In patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 (METex14) skipping mutations, capmatinib demonstrated a median objective response rate (ORR) ranging from 50.7% to 68.8% in first-line treatment, outperforming chemotherapy (23.1%-27.0% ORR) and immunotherapy (33.3% ORR).
  • In advanced NSCLC patients with MET amplification (METamp), capmatinib, alongside other MET inhibitors like tepotinib and savolitinib, showed promising results, particularly in patients progressing on epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs), with capmatinib being recommended for METamp NSCLC.
  • Across studies of MET inhibitors, capmatinib achieved a pooled ORR of 28.1% and a disease control rate (DCR) of 69.1%, with patients harboring METex14 skipping mutations showing higher 39.3% (95% confidence interval (CI), 0.296-0.522 (ORRs) (39.3%) and 77.8% (95% CI, 0.714-0.847 (DCRs) (77.8%) compared to those with MET protein overexpression or amplification.
  • Capmatinib demonstrated a satisfactory safety profile, with most adverse events being mild (grade 1 to 2) in 87.2% of patients. Common grade ≥3 adverse events included lower extremity edema (3.5%), alanine aminotransferase (ALT) elevation (2.4%), and lipase elevation (2.2%).
  • No specific safety concerns were highlighted for particular population types or subgroups in the reviewed studies.
  • Elderly patients are more likely to have MET exon 14 (METex14) skipping NSCLC and may benefit from MET TKI therapies like capmatinib. Additionally, METex14 skipping mutations are more frequent in adenocarcinoma (2.4%) and sarcomatoid (12.0%) subtypes, while less common in squamous histology (1.3%), indicating potential benefits for these specific histology subgroups.